Comments on: Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-colon-cancer-trial/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:14:03 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy | .gen Technologies Inc. http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-colon-cancer-trial/comment-page-1/#comment-112162 Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy | .gen Technologies Inc. Mon, 01 Mar 2010 20:37:24 +0000 http://www.xconomy.com/?p=36857#comment-112162 [...] http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-c... [...] [...] http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-c... [...]

]]> By: Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy « Biotech Beach Bum http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-colon-cancer-trial/comment-page-1/#comment-74372 Amgen’s Personalized Strategy for Cancer Pays Off in Big Colon Cancer Trial | Xconomy « Biotech Beach Bum Tue, 11 Aug 2009 14:56:09 +0000 http://www.xconomy.com/?p=36857#comment-74372 [...] http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-c... [...] [...] http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-c... [...]

]]> By: Trends Update — “Personalized Effectiveness”: Amgen Gets Prospective Data to Back KRAS-Vectibix Plan « The Cross-Border Biotech Blog http://www.xconomy.com/national/2009/08/10/amgens-personalized-strategy-for-cancer-pays-off-in-big-colon-cancer-trial/comment-page-1/#comment-74324 Trends Update — “Personalized Effectiveness”: Amgen Gets Prospective Data to Back KRAS-Vectibix Plan « The Cross-Border Biotech Blog Tue, 11 Aug 2009 12:03:46 +0000 http://www.xconomy.com/?p=36857#comment-74324 [...] note for companies thinking about companion diagnostics and personalized effectiveness is that the Amgen study was a prospective study that will support much more robust conclusions.  H/T [...] [...] note for companies thinking about companion diagnostics and personalized effectiveness is that the Amgen study was a prospective study that will support much more robust conclusions.  H/T [...]

]]>